Impact of <i>PNPLA3</i> Genotype on Hepatic Steatosis Response to Pemafibrate in MASLD With Dyslipidemia
Pemafibrate reduced hepatic steatosis preferentially in PNPLA3 CC carriers, whereas PNPLA3 G-allele carriers showed attenuated CAP improvement without weight loss. PNPLA3 polymorphism may influence steatosis-lowering efficacy of pemafibrate, underscoring the need for genotype-informed therapeutic strategies.
Authors
- Michihisa Moriguchi (ORCID: https://orcid.org/0000-0001-9779-4369)
- Seita Kataoka (ORCID: https://orcid.org/0000-0001-9347-5766)
- Takao Shirono
- Yuya Seko (ORCID: https://orcid.org/0000-0002-3658-5894)
- Kanji Yamaguchi (ORCID: https://orcid.org/0000-0002-0631-046X)
Institutions
- Kyoto Prefectural University of Medicine (JP)
Publication Details
- Journal
- Hepatology Research
- Published
- 2025-11-27
- DOI
- https://doi.org/10.1111/hepr.70083
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ministry of Education, Culture, Sports, Science and Technology